Table 2.
Patient characteristics of the studies included in the analyses.
| Trial Name | AFFIRM-AHF [9] | CONFRIM-HF [10] | IRON-HF [12] | FERRIC-HF [14] | EFFECT-HF [13] | FAIR-HF [11] | PRACTICE-ASIA-HF [15] |
|---|---|---|---|---|---|---|---|
| No. of Patients (Iron therapy/ Placebo) | 558/ 550 | 150/151 | 10/ 6 | 24/ 11 | 86/ 86 | 304/ 155 | 24/ 25 |
| Mean Age (Yr) (IT/P) | 71.2/ 70.9 | 68.8/ 69.5 | 66.9/ 68.9 | 64/ 62 | 63/ 64 | 67.8/ 67.4 | 61.1/ 64 |
| Women (%) (IT/P) | 44/ 45 | 45/ 49 | 30/ 33.3 | 29/ 27 | 30/ 20 | 52.3/ 54.8 | 25/ 20 |
| White Race (%) (IT/P) | 95/ 95 | 99/ 99 | N/A | 88/ 91 | N/A | 99.7/ 100 | 0/ 0 |
| Ischemic HF (%) (IT/P) | 47/ 47 | 83/ 83 | N/A | N/A | N/A | 80.6/ 79.4 | N/A |
| Anemia (%) (IT/P) | 52/ 57 | N/A | 100/ 100 | 50/ 55 | N/A | N/A | N/A |
| Mean Hb (g/dL) (IT/P) | 12.3/ 12.1 | 12.4/ 12.4 | 11.2/ 10.9 | 12.6/ 12.2 | 12.9/ 13 | 11.9/ 11.9 | 11.6/ 13.1 |
| Ferritin (ng/mL) (IT/P) | 83.9/ 88.5 | 57/ 57.1 | 185/ 95 | 62/ 88 | 48/ 53a | 52.5/ 60.1 | 91.4/ 84.1 |
| Mean TSAT (%) (IT/P) | 15.2/ 14.2 | 20.2/ 18.2 | 18.9/ 13.5 | 20/ 21 | 17.3/ 18.1a | 17.7/ 16.7 | 15.7/ 13.9 |
| Mean LVEF (%) (IT/P) | 32.6/ 32.7 | 37.1/ 36.5 | 25.2/ 30.7 | 30/ 29 | 33/ 31 | 31.9/ 33 | 38.8/ 33.2 |
| Premature Treatment Discontinuation (n) (IT/P) | 157/ 160 | 14/ 19 | N/A | 4/ 1 | 3/ 1 | 16/ 14 | N/A |
Abbreviations: TSAT - transferrin saturation, LVEF - left ventricular ejection fraction, Hb - hemoglobin, Yr - year, n - number, IT/P - Iron therapy/ placebo,
N/A - Not available.
AFFIRM-AHF [9]: A Randomized, Double-blind Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Subjects Admitted for Acute Heart Failure, CONFIRM-HF [10]: Ferric CarboxymaltOse evaluatioN on perFormance in patients with IRon deficiency in coMbination with chronic heart failure, IRON-HF [12]: A randomized trial to assess the effects of iron in heart failure patients with anemia, FERRIC-HF [14]: Intravenous iron sucrose in anemic and non-anemic iron deficient patients with CHF, EFFECT-HF [13]: Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency, FAIR-HF [11]: Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure, PRACTICE-ASIA-HF [15]: Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study.
Median values.